Activation of both canonical and non-canonical NF-κB pathways by DR3 signaling can potentially produce a synergistic effect52, which further ensures potent and sufficient activation of ILC2s to ameliorate T2DM. The gene discussed is NFKB1; the disease is type 2 diabetes mellitus.